🔗 Permalink

Inventor profile of:

James Bradley Lorens

City:

Bones

Country:

Norway

Published Applications:

Last publication date:

2024-08-22

Top Assignees for applications by James Bradley Lorens

The entities that hold a legal rights for patent applications filed by inventor Lorens James Bradley:

BerGenBio ASA 9 Bergen, Norway
BERGEN TEKNOLOGIOVERFØRING AS 5 Bergen, Norway
Bergen Teknologioverforing AS 3 Bergen, Norway
Bergen Teknologioverforing AS 1 Stedkode 70900, Norway
Bergen Teknologioverføring AS 1 Thormøhlensgate, Norway
BERGEBIO ASA 1 Bergen, Norway
BERGENBIO ASA 1 Bergn, Norway
BerGenBio ASA 1 Jonas Lies vei, Norway
BERGEN TEKNOLOGIOVERFORING AS 1 Stedkode, Norway
BerGenBio AS 1 BERGEN, Norway

Recent patent applications by Lorens James Bradley

James Bradley Lorens from Bones, NO has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-08-22

US20240277707A1

Human necessities

Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus

#2 | 2024-06-13

US20240190972A1

Chemistry; metallurgy

Anti-Axl Antagonistic Antibodies

#3 | 2023-12-21

US20230406941A1

Chemistry; metallurgy

Anti-AXL Antagonistic Antibodies

#4 | 2023-05-18

US20230149397A1

Human necessities

Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus

#5 | 2022-06-23

US20220195054A1

Chemistry; metallurgy

Anti-axl antagonistic antibodies

#6 | 2021-06-10

US20210171643A1

Chemistry; metallurgy

Anti-Axl antagonistic antibodies

#7 | 2020-07-09

US20200215064A1

Human necessities

Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus

#8 | 2019-06-13

US20190177419A1

Chemistry; metallurgy

Anti-Axl antagonistic antibodies

#9 | 2018-08-30

US20180246080A1

Physics

METHODS USING AXL AS A BIOMARKER OF EPITHELIAL-TO-MESENCHYMAL TRANSITION

#10 | 2018-06-07

US20180153888A1

Human necessities

COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS

#11 | 2017-12-07

US20170349658A1

Chemistry; metallurgy

Anti-Axl antagonistic antibodies

#12 | 2015-07-30

US20150212065A1

Physics

Methods using Axl as a biomarker of epithelial-to-mesenchymal transition

#13 | 2012-06-21

US20120159655A1

Physics

METHODS USING AXL AS A BIOMARKER OF EPITHELIAL-TO-MESENCHYMAL TRANSITION

InventorID:

1241120 ⎘